Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Santhera Pharmaceuticals Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was $212.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-46.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG EV-to-EBIT Related Terms
Santhera Pharmaceuticals Holding AG EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG EV-to-EBIT Chart
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-EBIT falls into.
Santhera Pharmaceuticals Holding AG's current Enterprise Value is $309.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-46.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a EV-to-EBIT of -6.70 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #999999 out of 371 companies in the Biotechnology industry.
Is Santhera Pharmaceuticals Holding AG's EV-to-EBIT too high?
Santhera Pharmaceuticals Holding AG's current EV-to-EBIT is -6.70. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #999999 out of 371 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #999999 out of 371 companies for EV-to-EBIT. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 13.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.76, based on 371 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current EV-to-EBIT is -6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Santhera Pharmaceuticals Holding AG (SPHDF) has a current EV-to-EBIT of -6.70. The stock's GF Value™ is $35.65, compared to a current price of $23.25 — trading 34.8% below its estimated fair value. The current EV-to-EBIT is -6.70. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current EV-to-EBIT is -6.70 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 34.8% below its estimated GF Value™ of $35.65.
Key valuation signals for SPHDF:
EV-to-EBIT: -6.70
GF Value™: $35.65 vs. price of $23.25 (34.8% below fair value)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
